Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

A comprehensive analysis has identified novel enhancers associated with neuronal development and disease.

The following is a summary of “Management of Psychosis and Schizophrenia by Primary Care GPs: A Cross-Sectional Study in ...

Generic drugs made in India are related to 54 per cent more severe adverse events, including hospitalisation, disability and ...

A new study from Karolinska Institutet shows that severe mental illness is more common in patients with chronic kidney ...

A machine learning model trained on electronic health record (EHR) data predicted progression to schizophrenia or bipolar ...

Now, new research from the Warren Center for Neuroscience Drug Discovery (WCNDD) offers hope. Scientists have identified a ...

CBD has shown promise as a treatment for psychosis in small studies and case reports. A large, international trial launching ...

Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food ...

Consultant psychiatrists have warned of a risk to patient health due to the shortage of beds for those suffering from mental ...

Genome-wide association studies (GWASs) have linked genetic variants to neuropsychiatric disorders, but their regulatory roles in non-coding regions remain largely unclear. Using the LUHMES neuronal ...

A new study has found that individuals who visit emergency departments (ED) due to hallucinogen use have a significantly higher risk of developing schizophrenia. The research, conducted by scientists ...